Core Viewpoint - The first government-guided pricing brain-computer interface (BCI) surgery in China has been successfully implemented, marking the formal inclusion of implantable BCI technology into the standardized medical service system [1][3]. Group 1: Clinical Application and Policy Support - The BCI technology is rapidly transitioning from laboratory research to clinical application, with the first surgery performed in Wuhan on a patient with spinal cord injury [1][3]. - The surgery utilized a 64-channel high-throughput flexible electrode device, which accurately monitors brain signals related to hand movement and sensation [3]. - The National Healthcare Security Administration has established specific pricing for BCI services, including a placement fee of 6,552 yuan per procedure, which provides a regulatory framework for clinical implementation [3][4]. Group 2: Industry Development and Market Potential - The successful surgery at Tongji Hospital is seen as a critical step towards the large-scale clinical application of BCI technology, fostering its accessibility and industrial development [4][5]. - Multiple cities in China have established clinical transformation centers for BCI, indicating a growing ecosystem and collaborative environment for BCI technology [4][6]. - The BCI market in China is projected to reach 3.2 billion yuan in 2024, with an expected growth rate of 18.81% year-on-year, indicating significant market potential [6][7]. Group 3: Investment and Competitive Landscape - Investment activity in the brain science and BCI sector is increasing, with 14 financing events reported in the first half of 2025, totaling over 800 million yuan [7]. - China has a unique advantage in the BCI industry, with over 800 core enterprises in the sector, primarily located in China and the United States [7]. - The BCI technology is becoming a focal point of global technological competition, with advancements in flexible, minimally invasive, and intelligent solutions being pursued [7].